Abstract | OBJECTIVE: RESEARCH DESIGN AND METHODS: RESULTS: Compared with placebo, fenofibrate decreased total cholesterol, non- HDL cholesterol, apolipoprotein B, and triglycerides and increased HDL cholesterol and apolipoprotein A-I (all P < 0.001) while tending to decrease LDL cholesterol (P = 0.069). Fenofibrate significantly improved percent flow-mediated dilator response to hyperemia by 48 +/- 5% (P < 0.001) and lowered plasma levels of high-sensitivity C-reactive protein ( hsCRP) relative to baseline measurements from 0.80 to 0.70 mg/l (P = 0.001) and fibrinogen levels by 16 +/- 3% (P < 0.001). Compared with placebo, fenofibrate therapy significantly increased plasma levels of adiponectin by 14 +/- 5% (P = 0.008) and increased insulin sensitivity (assessed by quantitative insulin sensitivity check index [QUICKI]) by 6 +/- 2% (P = 0.048). There were significant correlations between percent changes in adiponectin levels and percent changes in flow-mediated dilation (r = 0.401, P = 0.006), hsCRP (r = -0.443, P = 0.002), or QUICKI (r = 0.292, P = 0.049). Multivariate regression analysis showed that only changes in adiponectin levels persisted as an independent predictor of changes in flow-mediated dilation (r = 0.504, P = 0.013). Overall, we observed similar results in 24 patients with metabolic syndrome. CONCLUSIONS:
|
Authors | Kwang Kon Koh, Seung Hwan Han, Michael J Quon, Jeong Yeal Ahn, Eak Kyun Shin |
Journal | Diabetes care
(Diabetes Care)
Vol. 28
Issue 6
Pg. 1419-24
(Jun 2005)
ISSN: 0149-5992 [Print] United States |
PMID | 15920062
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Adiponectin
- Hypolipidemic Agents
- Intercellular Signaling Peptides and Proteins
- Placebos
- Fenofibrate
|
Topics |
- Adiponectin
- Blood Flow Velocity
(drug effects)
- Body Mass Index
- Brachial Artery
(drug effects, physiopathology)
- Cross-Over Studies
- Double-Blind Method
- Endothelium, Vascular
(drug effects, physiopathology)
- Female
- Fenofibrate
(therapeutic use)
- Humans
- Hyperemia
(drug therapy, physiopathology)
- Hypertriglyceridemia
(blood, drug therapy, physiopathology)
- Hypolipidemic Agents
(therapeutic use)
- Insulin Resistance
- Intercellular Signaling Peptides and Proteins
(blood)
- Male
- Metabolic Syndrome
(blood, drug therapy, physiopathology)
- Middle Aged
- Patient Selection
- Placebos
|